Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger's Disorder: A 14-Week, Prospective, Open-Label Study
- 1 June 2009
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Journal of Child and Adolescent Psychopharmacology
- Vol. 19 (3), 265-274
- https://doi.org/10.1089/cap.2008.093
Abstract
Objective: The aim of this study was to determine the effectiveness and tolerability of aripiprazole for irritability in pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger's disorder. Method: This is a 14-week, prospective, open-label investigation of aripiprazole in 25 children and adolescents diagnosed with PDD-NOS or Asperger's disorder. Primary outcome measures included the Clinical Global Impressions–Improvement (CGI-I) scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I). Results: Twenty-five subjects, ages 5–17 years (mean 8.6 years) received a mean final aripiprazole dosage of 7.8 mg/day (range 2.5–15 mg/day). Full-scale intelligence quotient (IQ) scores ranged from 48 to 122 (mean 84). Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final CGI-I of 1 or 2 (very much or much improved) and a 25% or greater improvement on the ABC-I. The final mean CGI-I was 1.6 (p ≤ 0.0001). ABC-I scores ranged from 18 to 43 (mean 29) at baseline, whereas scores at week 14 ranged from 0 to 27 (mean 8.1) (p ≤ 0.001). Aripiprazole was well tolerated. Mild extrapyramidal symptoms (EPS) were reported in 9 subjects. Age- and sex-normed body mass index (BMI) increased from a mean value of 20.3 at baseline to 21.1 at end point (p ≤ 0.04). Prolactin significantly decreased from a mean value of 9.3 at baseline to 2.9 at end point (p ≤ 0.0001). No subject exited the study due to a drug-related adverse event. Conclusions: These preliminary data suggest that aripiprazole may be effective and well tolerated for severe irritability in pediatric patients with PDD-NOS or Asperger's disorder. Larger-scale placebo-controlled studies are needed to elucidate the efficacy and tolerability of aripiprazole in this understudied population.Keywords
This publication has 45 references indexed in Scilit:
- Aripiprazole Treatment of Children and Adolescents with Tourette Disorder or Chronic Tic DisorderJournal of Child and Adolescent Psychopharmacology, 2008
- Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorderDepression and Anxiety, 2007
- APilot Study of Aripiprazole in Children and Adolescents with Tourette's DisorderJournal of Child and Adolescent Psychopharmacology, 2006
- Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and Blinded Discontinuation After 6 MonthsAmerican Journal of Psychiatry, 2005
- Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective DataAmerican Journal of Psychiatry, 2004
- Quetiapine in Nine Youths with Autistic DisorderJournal of Child and Adolescent Psychopharmacology, 2004
- Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental DisordersJournal of Clinical Psychopharmacology, 1999
- Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic DisorderJournal of Child and Adolescent Psychopharmacology, 1999
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970